Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial

RCT (n=795) found that addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in ACS patients (6.0% vs 9.5%, p=0.09), but it did increase mortality rate (2% vs 0.3%, p=0.017).

Circulation